Searching for source:EMA

31,109 results
Record publications over time
Ironsift results are limited for unregistered users. Register or log in to see all records.

EU Clinical Trial 2019-000890-21 – EMA – May 21, 2019

A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CHILDREN 6 TO 17 YEARS OF AGE IN INDIA

Main objective of the trial: To describe the safety profile of 13vPnC in pediatric subjects 6 to 17 years of age.
Full record
Register to view full records and advanced analytics.

EU Clinical Trial 2018-002816-29 – EMA – May 21, 2019

A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Multiple Myeloma (DREAMM 4)

Main objective of the trial: Part 1: To determine safety, tolerability and to establish the RP2D of the combination of GSK2857916 with pembrolizumab in subjects with RRMM) Part 2: To assess the clinical activity of the combination treatment with GSK2...
Full record

EU Clinical Trial 2018-000616-25 – EMA – May 20, 2019

Pharmacokinetics of fosfomycin: a study in patients with prolonged treatment for urinary tract infection

Main objective of the trial: To evaluate the pharmacokinetics of fosfomycine in patients with prolonged fosfomycin therapy to treat urinary tract infection
Full record

EU Clinical Trial 2018-003379-37 – EMA – May 20, 2019

IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY.

Main objective of the trial: To determine the optimal dose of VLA15 in healthy adults aged 18 - 65 years up to Day 85.
Full record

EU Clinical Trial 2018-004802-24 – EMA – May 20, 2019

Optimizing timing of glucocorticoid treatment in children with congenital adrenal hyperplasia

Main objective of the trial: To study the effects of 2 standard treatment timing strategies for glucocorticoid dosage on androgen concentration in CAH children: a. highest dosage in the morning, b. highest dosage in the evening. Wij willen graag eval...
Full record

EU Clinical Trial 2018-002264-57 – EMA – May 20, 2019

A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis

Main objective of the trial: To evaluate the efficacy and safety of upadacitinib versus dupilumab for the treatment of adult subjects with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Full record

EU Clinical Trial 2017-005028-11 – EMA – May 20, 2019

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)

Main objective of the trial: To evaluate the long-term safety and tolerability of baricitinib in patients with SLE.
Full record

EU Clinical Trial 2016-003704-31 – EMA – May 17, 2019

Impact on the intestinal microbiota during antibiotic treatment

Main objective of the trial: The objective of the study is: (1) to identify the composition and diversity of the intestinal microbiota and the presence of resistant bacteria and resistance genes, before and up to 1 years after antibiotic treatment (2...
Full record

EU Clinical Trial 2018-000406-36 – EMA – May 16, 2019

Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE)

Main objective of the trial: The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction (EGJ) ad...
Full record

EU Clinical Trial 2017-004684-12 – EMA – May 16, 2019

Nitric Oxide during Cardio Pulmonary Bypass during surgery for congenital heart defects: A Randomised Controlled Trial.

Main objective of the trial: To investigate in a double blind randomized controlled trial in children undergoing open heart surgery if NO exposure during CPB reduces the postoperative duration of invasive mechanical ventilation (defined as ventilator...
Full record

EU Clinical Trial 2018-003411-21 – EMA – May 16, 2019

A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS - intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib

Main objective of the trial: To evaluate the percentage of subjects with at least 35% spleen volume reduction in the fedratinib and the BAT arms. Evaluar el porcentaje de pacientes con una reducción del volumen esplénico de al menos el 35 % en el gru...
Full record
Register to view full records and use our APIs.

EU Clinical Trial 2018-004558-30 – EMA – May 16, 2019

Synovial ultrasound as primary outcome in a 3-arm, randomized, open-label, parallel active controlled, multicenter international study comparing baricitinib, alone and combined with MTX versus TNF-alfa inhibitor in rheumatoid arthritis patients: Searching for synovium predictors of response.

Main objective of the trial: The main objective of the study is to demonstrate non-inferiority of the response of MSKUS-assessed synovitis (i.e. B-mode and Doppler mode synovitis) to baricitinib treatment, alone plus combined with MTX (arm1 + arm2) v...
Full record

EU Clinical Trial 2018-001305-82 – EMA – May 16, 2019

Study on the advantages of local post-operative infiltration in forefoot surgery.

Main objective of the trial: To control pain after outpatient forefoot surgery controlar de forma eficaz el dolor postoperatorio tras la cirugía ambulatoria de antepié
Full record

EU Clinical Trial 2017-005038-53 – EMA – May 16, 2019

Randomized double-blind, placebo-controlled study evaluate the efficacy and mechanisms involved in immunotherapy Sublingual specifies with Pru p 3 (Pru p 3-ITSL) in patients with allergy to nsLTP with severe symptoms in its response to Peach, peanut, artemisia and olive.

Main objective of the trial: Evaluate the efficacy and safety of specific sublingual immunotherapy with Pru p 3 (SLIT-Prup3) in patients with allergy to nsLTP with severe symptoms in their response to peach, peanut, artemisia and olive trees by condu...
Full record

EU Clinical Trial 2018-002155-15 – EMA – May 16, 2019

A randomized, open label, phase II trial of Anti-PD1, TSR-042, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation

Main objective of the trial: Evaluate the progression-free survival (PFS) of patients with high risk locally advanced cervical cancer (HRLACC) who have achieved a partial (PR) or complete response (CR) after concurrent chemotherapy and radiation ther...
Full record

EU Clinical Trial 2018-004180-31 – EMA – May 16, 2019

Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label extension for patients completing study 3119002

Main objective of the trial: The primary objective, in addition to continuing treatment for subjects in this study, is to evaluate long-term safety of oral levosimendan in amyotrophic lateral sclerosis (ALS) patients. El objetivo principal de este es...
Full record

EU Clinical Trial 2017-003064-13 – EMA – May 16, 2019

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

Main objective of the trial: Demonstrate the efficacy of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA)
Full record

EU Clinical Trial 2018-001836-24 – EMA – May 16, 2019

A 12-month, open-label, multicenter, randomized, safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) study of two regimens of anti-CD40 monoclonal antibody, CFZ533 vs. standard of care control, in adult de novo liver transplant recipients with a 12-month additional follow-up (CONTRAIL I)

Main objective of the trial: To evaluate the rate of composite efficacy failure (Biopsy Proven Acute Rejection (BPAR), graft loss or death) with CFZ533 regimens compared to TAC Control at Month 12 post-transplantation. Evaluar el índice compuesto de...
Full record

EU Clinical Trial 2018-002096-17 – EMA – May 16, 2019

Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumor of bone: a multicenter phase II study "REDUCE"

Main objective of the trial: The primary objective of the trial is to evaluate the risk versus benefit of denosumab in maintenance setting in patients requiring long-term use (> 1 year) of denosumab. For that purpose, the treatment schedule with redu...
Full record

EU Clinical Trial 2018-003012-51 – EMA – May 16, 2019

A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib

Main objective of the trial: To determine the efficacy of savolitinib in combination with osimertinib in patients with EGFRm+, MET+ (determined centrally by FISH), locally advanced or metastatic NSCLC who have progressed on osimertinib. Determinar la...
Full record

EU Clinical Trial 2017-003065-95 – EMA – May 16, 2019

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS

Main objective of the trial: Demonstrate the efficacy of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS)
Full record
Register to view full records and disable ads.

EU Clinical Trial 2018-004237-32 – EMA – May 15, 2019

A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surgery.

Main objective of the trial: To determine the efficacy of JNJ-70033093 in preventing total VTE events (proximal and/or distal DVT [asymptomatic confirmed by venography assessment or objectively confirmed symptomatic], nonfatal PE), or any death durin...
Full record

EU Clinical Trial 2018-002134-20 – EMA – May 15, 2019

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma

Main objective of the trial: To assess the efficacy of durvalumab monotherapy when given with transarterial chemoembolization (TACE) compared to TACE + placebo
Full record

EU Clinical Trial 2019-000305-79 – EMA – May 14, 2019

An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients with Charcot-Marie Tooth (CMT) Disease Types 1 and X Previously Enrolled in Study A083-03

Main objective of the trial: To evaluate the long-term safety and pharmacodynamic (PD) effects of ACE-083 in patients with facioscapulohumeral muscular dystrophy (FSHD) previously enrolled in Study A083-02 and in patients with Charcot Marie Tooth (CM...
Full record

EU Clinical Trial 2018-004211-42 – EMA – May 14, 2019

An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer

Main objective of the trial: To evaluate the efficacy of balixafortide + eribulin versus eribulin monotherapy on (i) PFS in the Overall Population and (ii) PFS and objective response rate (ORR) in the 3rd line + population. Evaluar la eficacia de bal...
Full record

EU Clinical Trial 2018-003682-34 – EMA – May 14, 2019

A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients

Main objective of the trial: 1. To evaluate the efficacy of clazakizumab in preventing all-cause composite allograft loss due to CABMR (defined as return to dialysis, allograft nephrectomy, re-transplantation, estimated glomerular filtration rate (eG...
Full record

EU Clinical Trial 2018-001715-79 – EMA – May 14, 2019

A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects with Multiple Myeloma – The GENESIS Study

Main objective of the trial: To demonstrate the superiority of one dose of BL-8040 + G-CSF over placebo + G-CSF to mobilize ≥6.0 x 10^6 CD34+ cells/kg in up to 2 apheresis sessions in preparation for autologous hematopoietic cell transplantation (aut...
Full record

EU Clinical Trial 2018-003712-45 – EMA – May 14, 2019

A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis

Main objective of the trial: To establish the efficacy of ruxolitinib cream in participants with AD (IGA).
Full record

EU Clinical Trial 2018-002965-20 – EMA – May 14, 2019

A randomized, open, 2 treatment arms clinical trial to evaluate the efficacy and safety of cervical ripening with Foley catheter vs cervical ripening with intravaginal synthetic analogue of prostaglandins E1 (MISOPROSTOL).

Main objective of the trial: To compare the efficacy and safety of the intracervical Foley catheter and vaginal misoprostol for cervical ripening in pregnant women with a medical indication for labor induction with an unfavorable cervical state compa...
Full record

EU Clinical Trial 2018-003804-37 – EMA – May 14, 2019

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTI CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF 04965842 CO ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO <18 YEARS OF AGE WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Main objective of the trial: To assess the efficacy of PF 04965842 compared with placebo when co administered with background medicated topical therapy in adolescent participants 12 to <18 years of age with moderate-to-severe AD.
Full record

EU Clinical Trial 2017-001972-46 – EMA – May 14, 2019

Reaching Protein Target with SmofKabiven® extra Nitrogen Versus Olimel N9E: A Prospective, Randomised, Active-controlled, Patient-blinded, Multicentre Clinical Trial During the Early Phase of Acute Critical Illness

Main objective of the trial: To explore the efficacy of SmofKabiven® extra Nitrogen compared with Olimel N9E in reducing the cumulative protein deficit with the same caloric target during the early phase of acute critical illness in haemodynamically...
Full record
Register to view full records and receive email notifications.

EU Clinical Trial 2018-004055-20 – EMA – May 14, 2019

Immunogenicity and Safety of a Purified Vero Rabies Vaccine – Serum Free in Comparison with Verorab® and Imovax® Rabies, in a Simulated Rabies Post-exposure Regimen in Healthy Adults in France

Main objective of the trial: To demonstrate that Vero Rabies Vaccine generation 2 (VRVg-2) is non-inferior to Verorab and Imovax Rabies vaccines when co-administered with Human Rabies Immunoglobulins (HRIG), in terms of proportion of subjects achievi...
Full record

EU Clinical Trial 2018-004484-31 – EMA – May 14, 2019

Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis

Main objective of the trial: To investigate the effect of semaglutide subcutaneous (s.c.) 2.4 mg once-weekly on liver fibrosis compared with placebo in subjects with NASH and compensated fibrosis stage 4 Investigar el efecto de semaglutida s.c. 2,4 m...
Full record

EU Clinical Trial 2018-004785-33 – EMA – May 14, 2019

A 12-month, Prospective, Open-label, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Treatment Naïve Patients (according to standard clinical practice) with Diabetic Macular Edema

Main objective of the trial: The objective of this study is to evaluate the efficacy and safety of OZURDEX in patients with DME when used in a real world setting in Spain and Portugal. El objetivo de este estudio es evaluar la eficacia y la seguridad...
Full record

EU Clinical Trial 2018-002894-23 – EMA – May 14, 2019

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

Main objective of the trial: Evaluate the efficacy of pemigatinib versus gemcitabine plus cisplatin in the first-line treatment of participants with cholangiocarcinoma with FGFR2 rearrangement.
Full record

EU Clinical Trial 2019-000678-41 – EMA – May 13, 2019

CABRAMET - A phase 2 study of cabozantinib in renal cell carcinoma (mRCC) with brain metastases

Main objective of the trial: To evaluate the non progression rate in brain metastases at 3 months. Evaluer le taux de non progression des métastases cérébrales à 3 mois.
Full record

EU Clinical Trial 2019-000505-72 – EMA – May 13, 2019

Pragmatic trial baricitinib versus First biological in “Tight Control” Patients suffering from Rheumatoid Arthritis (PERFECT)

Main objective of the trial: To demonstrate non-inferiority of a T2T strategy in which conventional synthetic disease modifying drugs (csDMARDs) refractory RA patients are initially treated with tsDMARD baricitinib versus the comparable T2T strategy...
Full record

EU Clinical Trial 2018-002263-26 – EMA – May 13, 2019

Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder

Main objective of the trial: The objective of this study is to identify the eligibility criteria for treatment with Li in BDI in terms of response, safety and tolerability Primary Objective: To evaluate the predictive values of the biomarkers collect...
Full record

EU Clinical Trial 2018-001023-38 – EMA – May 13, 2019

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (KarMMa-3)

Main objective of the trial: Compare the efficacy of bb2121 to standard triplet regimens in subjects with RRMM as measured by progression-free survival (PFS) Comparez l'efficacité de bb2121 par rapport aux schémas thérapeutiques triplets standard che...
Full record

EU Clinical Trial 2018-004116-22 – EMA – May 13, 2019

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)

Main objective of the trial: 1. To compare pembrolizumab plus docetaxel plus prednisone to placebo plus docetaxel plus prednisone with respect to overall survival (OS) 2. To compare pembrolizumab plus docetaxel plus prednisone to placebo plus docetax...
Full record

EU Clinical Trial 2018-001233-40 – EMA – May 10, 2019

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction and Decreased Exercise Tolerance

Main objective of the trial: To evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by CPET following 20 weeks of treatment with omecamtiv mecarbil or placebo
Full record
Register to view full records and disable ads.

EU Clinical Trial 2018-001152-35 – EMA – May 10, 2019

A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children with Sickle Cell Disease (PNEU–SICKLE)

Main objective of the trial: - To evaluate the safety and tolerability of V114 with respect to the proportion of participants with adverse events (AEs) - To evaluate the anti-pneumococcal polysaccharide (PnPs) serotype-specific Immunoglobulin G (IgG)...
Full record

EU Clinical Trial 2017-000220-10 – EMA – May 10, 2019

A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer

Main objective of the trial: Assessment of toxicity of combined treatment with ipilimumab, nivolumab, pegylated liposomal doxorubicin and cyclophosphamide (ipi/nivo/chemo) Assessment of clinical response in ipi/nivo/chemo group compared to chemo only...
Full record

EU Clinical Trial 2018-004234-15 – EMA – May 10, 2019

A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease.

Main objective of the trial: The primary objective of this study is to determine whether the overall response rate (ORR) in the experimental arm (400 mg) is non-inferior to the control arm (600 mg) based on local tumor assessments (RECIST version1.1)...
Full record

EU Clinical Trial 2018-002734-20 – EMA – May 10, 2019

An Open Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Naive or Have Not Recently Received Complement Inhibitor Therapy

Main objective of the trial: The primary objective of the study is to demonstrate a reduction in intravascular hemolysis by REGN3918 over 26 weeks of treatment in patients with active PNH who are treatment naive to complement inhibitor therapy or hav...
Full record

EU Clinical Trial 2018-003809-26 – EMA – May 10, 2019

A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905)

Main objective of the trial: 1. To compare pathologic complete response (pCR) rates obtained in Arm A (preoperative pembrolizumab [MK-3475] and radical cystectomy [RC] + pelvic lymph node dissection [PLND]) and Arm B (RC+PLND), based on central patho...
Full record

EU Clinical Trial 2019-000618-13 – EMA – May 10, 2019

Bevacizumab and tocotrienol in recurrent ovarian cancer. A marker based phase II trial

Main objective of the trial: To investigate the effect of bevacizumab and tocotrienol based on the level of methylated circulating tumor specific HOXA9 DNA (HOXA9 meth-ctDNA) after the first treatment cycle assessed by progression free survival
Full record

EU Clinical Trial 2018-001127-40 – EMA – May 10, 2019

A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE UNABLE TO TOLERATE FULL-DOSE CHEMOTHERAPY

Main objective of the trial: Cohort A • To make a preliminary assessment of the anti-tumor activity of mosunetuzumab in patients with best response of partial response (PR)following first-line therapy for Diffuse Large B-Cell Lymphoma (DLBCL) • To ev...
Full record

EU Clinical Trial 2018-003359-40 – EMA – May 9, 2019

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of JTE-451 Administered for 16 Weeks in Subjects with Moderate to Severe Plaque Psoriasis (IMPACT-PS)

Main objective of the trial: The primary objective is to evaluate the efficacy of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis compared with placebo.
Full record

EU Clinical Trial 2019-000670-37 – EMA – May 9, 2019

Imaging tumor-infiltrating CD8+ T-cells in non-small cell lung cancer upon neo-adjuvant treatment with Durvalumab (MEDI4736).

Main objective of the trial: The overall aim of this study is to demonstrate increase of tumor-infiltrating CD8+ T cells in non-small cell lung cancer during neo-adjuvant treatment with durvalumab (MEDI4736). Het primaire doel van deze studie is het...
Full record